Cargando…
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
One year into the Coronavirus Disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), effective treatments are still needed(1-3). Monoclonal antibodies, given alone or as part of a therapeutic cocktail, have shown promising results in patients, raisin...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal Experts
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899470/ https://www.ncbi.nlm.nih.gov/pubmed/33619476 http://dx.doi.org/10.21203/rs.3.rs-235272/v1 |